SCHEMBL22266259

SCHEMBL22266259

NC(=O)CCCCOCCOCCO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
GAA P10253 1/20 0.50
THRB P10828 1/20 0.50
HTT P42858 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
EPHX2 P34913 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
TARDBP Q13148 1/20 0.32
FAAH O00519 1/20 0.32
TP53 P04637 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
SOAT1 P35610 1/20 0.32
GPR84 Q9NQS5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8263454 0.98 MEN1 (0.54) KMT2AMEN1GAATHRBHTT
SCHEMBL22266235 0.98 GAA (0.52) KMT2AMEN1GAATHRBHTT
SCHEMBL22266293 0.95 GAA (0.55) KMT2AMEN1GAATHRBHTT
SCHEMBL8881923 0.95 GAA (0.55) KMT2AMEN1GAATHRBHTT
Triethylene Glycol SCHEMBL8995564 0.95 MEN1 (0.55) KMT2AMEN1GAATHRBHTT
SCHEMBL28674740 0.93 MEN1 (0.52) KMT2AMEN1GAATHRBHTT
SCHEMBL22266241 0.91 TSHR (0.46) KMT2AMEN1GAATHRBHTT
SCHEMBL8883206 0.91 TSHR (0.50) KMT2AMEN1GAATHRBHTT
SCHEMBL22266242 0.88 TSHR (0.48) KMT2AMEN1GAATHRBHTT
SCHEMBL22266255 0.88 GAA (0.57) KMT2AMEN1GAATHRBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210139458-A1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS ARVINAS OPERATIONS, INC. 2021-05-13 US disclosed
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides ARVINAS OPERATIONS, INC. (US) 2020-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139458-A1 TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS MDM2, CRBN, VHL KMT2A 1473/4885MEN1 2168/4885GAA 2975/4885
US-10723717-B2 Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides CRBN, ARAF, VHL KMT2A 1975/4885MEN1 2317/4885GAA 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.